Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Siliq

- PMLiVE

US and Indian regulators forge closer ties

FDA signs new agreement with India's Ministry of Health and Family Welfare

Novartis building

Novartis enters PD-1 race via CoStim acquisition

Expands presence in cancer immunotherapies

- PMLiVE

FDA backs BioMarin drug for rare enzyme disorder

Vimizim is first drug approved in US under rare paediatric disease priority review

- PMLiVE

FDA knocks back J&J and Bayer’s Xarelto in ACS

Follows unanimous negative committee vote

- PMLiVE

FDA knocks back Durect’s painkiller

Regulator wants more safety information for Posidur

- PMLiVE

FDA clears J&J’s Imbruvica for leukaemia

Adds to cancer drug's lymphoma indication

- PMLiVE

FDA to review safety of AZ’s saxagliptin

Diabetes drug linked to heart failure

- PMLiVE

FDA deems GSK anaemia drug a ‘breakthrough’

US regulator will accelerate review of Promacta

- PMLiVE

FDA approves sleep disorder drug for blind people

Vanda Pharmaceuticals wins backing for Hetlioz to improve a person’s body clock

Novartis building

Novartis planning thousands more job cuts, says paper

NZZ am Sonntag claims pharma company plans to transfer roles to India

Novartis building

CHMP denies Novartis’ heart failure drug

Panel refuses to recommend serelaxin for use in EU

Novartis building

CHMP backs Xolair for severe hives

Novartis set to expand indications for asthma drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links